FDA Approves Livsayis, Seventh RNAi Drug from Alnylam's Platform
The US Food and Drug Administration approved Livsayis (cemdisiran) for generalized myasthenia gravis. Alnylam discovered the drug, and Regeneron will commercialize it.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The US Food and Drug Administration (FDA) has approved Livsayis (cemdisiran) for generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies, according to Alnylam Pharmaceuticals, as reported by TradingView. It is the seventh RNAi therapy from Alnylam to win FDA approval and the first RNAi drug approved for gMG.
Alnylam scientists discovered Livsayis and advanced it into Phase 2 before it became part of a collaboration with Regeneron. Since 2024, Regeneron has handled development, manufacturing and commercialization. Under the agreement, Alnylam receives a $25 million payment for the approval and is eligible for tiered royalties of up to 15% on global net sales. The subcutaneous drug silences the gene that produces complement component 5 (C5) and is given four times a year.
Alnylam CEO Yvonne Greenstreet said that seven FDA-approved medicines from the company in under nine years show RNAi is becoming an important platform for new drugs.
why it matters
For markets, the news matters mainly as a confirmation of Alnylam's platform and its partnership with Regeneron. The approval gives patients with a rare autoimmune disease a new option, while the direct financial impact for Alnylam is so far limited to a one-time payment and future royalties that depend on sales.
market impact
Alnylam: approval and Regeneron royalties add to income, with a modest effect so far
- Alnylam shares pressure up — one-time $25 million payment and future royalties on sales
tags
instruments
on polymarket
sources
- Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years — TradingView, 19 November 2026 at 12:00 UTC
- Alnylam Collaborator Regeneron Secures FDA Approval Of Livsayis™ (Cemdisiran) — Reuters, 19 November 2026 at 13:01 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗